Home › Compare › IDDWF vs ABBV
IDDWF yields 1.12% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, IDDWF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IDDWF + ABBV for your $10,000?
Indutrade AB (publ) manufactures, develops, and sells components, systems, and services to various industries worldwide. It operates through eight segments: Benelux, DACH, Finland, Flow Technology, Fluids and Mechanical Solutions, Industrial Components, Measurement and Sensor Technology, and UK. The company also provides components and systems for controlling, measuring, monitoring, and regulating flows, as well as for industrial production and maintenance; hydraulic and mechanical components; medical technology equipment; measurement instruments and systems, sensors, control and regulating technology, and monitoring equipment; and custom-manufactured products, design solutions, aftermarket and assembly services, and customization services. In addition, it provides valves, hydraulic and industrial equipment, measurement technology and automation products, construction materials, filters, pipes and pipe systems, auto repair, tools and transmission, industrial springs, water and wastewater, lighting, chemical technology, fasteners, electronics, vehicles, energy, springs, piston rings, press work, and valve channels. The company was incorporated in 1919 and is based in Kista, Sweden.
Full IDDWF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.